Boehringer Ingelheim: EU grants marketing authorisation for Giotrif® for the treatment of patients with advanced squamous cell carcinoma (SqCC) of the lung

• Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases.1,2 • Approval of Giotrif® is based on results of the LUX-Lung 8 study, … Read the full press release →